Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 11 unusual trades.
Delving into the details, we found 18% of traders were bullish, while 81% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $224,116, and 6 were calls, valued at $214,772.
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $250.0 to $320.0 for Amgen over the last 3 months.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Amgen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Amgen's substantial trades, within a strike price spectrum from $250.0 to $320.0 over the preceding 30 days.
Amgen 30-Day Option Volume & Interest Snapshot
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | SWEEP | BULLISH | 01/17/25 | $11.85 | $11.15 | $11.85 | $320.00 | $66.3K | 3.0K | 83 |
| AMGN | PUT | SWEEP | NEUTRAL | 04/05/24 | $2.47 | $2.27 | $2.45 | $277.50 | $64.4K | 252 | 285 |
| AMGN | PUT | TRADE | BULLISH | 07/19/24 | $26.65 | $26.6 | $26.6 | $300.00 | $53.2K | 517 | 20 |
| AMGN | PUT | SWEEP | BEARISH | 08/16/24 | $13.3 | $13.25 | $13.25 | $270.00 | $39.7K | 1.0K | 57 |
| AMGN | PUT | SWEEP | BEARISH | 06/20/25 | $17.65 | $17.55 | $17.65 | $250.00 | $38.8K | 19 | 38 |
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Following our analysis of the options activities associated with Amgen, we pivot to a closer look at the company's own performance.
Present Market Standing of Amgen
- With a trading volume of 847,587, the price of AMGN is up by 0.11%, reaching $283.36.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 23 days from now.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
